Literature DB >> 6831397

Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases.

B Fisher, N Gunduz, E A Saffer.   

Abstract

In many animal models, primary tumor removal produces increased proliferation of cells in metastatic foci. The present investigations using a murine mammary tumor were carried out to determine how a variation in the time interval between primary tumor removal and administration of a single dose of cyclophosphamide (CY) affected labeling indices of residual tumor cells, their growth, and animal survival. The CY (240 mg/kg) had a more favorable effect when given on the day of tumor removal than 3 days after, a time when the labeling index (LI) of metastases was at a peak. It was least effective if given at 7 days following primary tumor excision, when the LI had returned to the preoperative level. The greatest effect occurred when the CY was given prior to operation. It completely prevented the increase in LI resulting from tumor removal, more effectively suppressed the growth of residual tumor, and prolonged survival to a greater extent than was noted under any other circumstance. The interval between tumor removal and administration of a relatively small amount of CY (60 mg/kg) was critical. When given on the day of tumor removal, an increase in LI of the residual focus occurred which was greater than that occurring as a result of tumor removal. When given 3 days after tumor removal, the smaller dose was almost as effective in suppressing LI as was the larger. From a kinetic standpoint, there was no advantage in reducing the tumor burden prior to the use of chemotherapy. The tumor response in this model suggests that, for the most effective control of metastases, the largest tolerable dose of chemotherapy would best be used at the time of or before primary tumor removal. The results provide a biological rationale for the use of perioperative adjuvant chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6831397

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  81 in total

1.  Effect of 5-fluorouracil plus interferon on the integrity of colonic anastomoses covering with fibrin glue.

Authors:  D Kanellos; K Blouhos; M G Pramateftakis; I Kanellos; H Demetriades; L Sakkas; D Betsis
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

2.  Wound recurrence after laparoscopic colectomy for cancer. New rationale for intraoperative intraperitoneal chemotherapy.

Authors:  P Jacquet; P H Sugarbaker
Journal:  Surg Endosc       Date:  1996-03       Impact factor: 4.584

3.  Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study.

Authors:  K S Tewari; J J Java; R N Eskander; B J Monk; R A Burger
Journal:  Ann Oncol       Date:  2015-10-20       Impact factor: 32.976

4.  Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes.

Authors:  Felipe A Calvo; Virginia Morillo; Marcos Santos; Javier Serrano; Marina Gomez-Espí; Marcos Rodriguez; Emilio Del Vale; Jose Luis Gracia-Sabrido; Carlos Ferrer; Claudio Sole
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-01       Impact factor: 4.553

5.  Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.

Authors:  Bhavna Murali; Qihao Ren; Xianmin Luo; Douglas V Faget; Chun Wang; Radia Marie Johnson; Tina Gruosso; Kevin C Flanagan; Yujie Fu; Kathleen Leahy; Elise Alspach; Xinming Su; Michael H Ross; Barry Burnette; Katherine N Weilbaecher; Morag Park; Gabriel Mbalaviele; Joseph B Monahan; Sheila A Stewart
Journal:  Cancer Res       Date:  2018-08-09       Impact factor: 12.701

6.  Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.

Authors:  Takahiro Kogawa; Takeo Fujii; Jimin Wu; Kenichi Harano; Tamer M Fouad; Diane D Liu; Yu Shen; Hiroko Masuda; Savitri Krishnamurthy; Mariana Chavez-MacGregor; Bora Lim; Rashmi K Murthy; Vicente Valero; Debu Tripathy; Naoto T Ueno
Journal:  Oncologist       Date:  2020-01-31

7.  Mathematical Modeling of Tumor-Tumor Distant Interactions Supports a Systemic Control of Tumor Growth.

Authors:  Sebastien Benzekry; Clare Lamont; Dominique Barbolosi; Lynn Hlatky; Philip Hahnfeldt
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

8.  Growth of metastases of the mouse adenocarcinoma EO 771: an allometric relationship between growth of the primary tumors and their metastases.

Authors:  I D Bassukas; B Maurer-Schultze
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

Review 9.  Intraportal chemotherapy for colorectal hepatic metastases.

Authors:  U T Laffer; U Metzger
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

10.  State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.

Authors:  Arnd Honig; Lorenz Rieger; Marc Sutterlin; Diethelm Wallwiener; Johannes Dietl; Erich-Franz Solomayer
Journal:  Ger Med Sci       Date:  2005-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.